Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China
· Delayed Price · Currency is CNY 3.180
+0.010 (0.32%)
Mar 10, 2026, 2:15 PM CST
SHE:002589 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 4,705 | 4,444 | 4,920 | 6,165 | 5,881 | 7,826 | Upgrade
|
| Market Cap Growth | 5.87% | -9.67% | -20.19% | 4.83% | -24.86% | -31.99% | Upgrade
|
| Enterprise Value | 6,401 | 7,022 | 3,501 | 7,785 | 11,382 | 10,805 | Upgrade
|
| Last Close Price | 3.17 | 2.97 | 3.24 | 4.08 | 3.89 | 5.15 | Upgrade
|
| PE Ratio | - | 215.52 | 242.17 | - | 44.83 | 29.95 | Upgrade
|
| Forward PE | - | 8.02 | 8.02 | 8.02 | 8.45 | 12.23 | Upgrade
|
| PS Ratio | 0.64 | 0.56 | 0.61 | 0.50 | 0.28 | 0.29 | Upgrade
|
| PB Ratio | 0.86 | 0.78 | 0.87 | 1.07 | 0.61 | 0.74 | Upgrade
|
| P/TBV Ratio | 1.00 | 0.90 | 1.04 | 1.33 | 0.91 | 1.23 | Upgrade
|
| P/FCF Ratio | 170.41 | 90.86 | - | 17.51 | - | - | Upgrade
|
| P/OCF Ratio | 24.86 | 27.70 | 59.67 | 11.79 | 13.28 | 18.86 | Upgrade
|
| PEG Ratio | - | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | Upgrade
|
| EV/Sales Ratio | 0.87 | 0.88 | 0.44 | 0.63 | 0.54 | 0.40 | Upgrade
|
| EV/EBITDA Ratio | 54.16 | 36.51 | 26.75 | 46.91 | 10.22 | 6.31 | Upgrade
|
| EV/EBIT Ratio | - | 228.27 | - | - | 13.99 | 7.60 | Upgrade
|
| EV/FCF Ratio | 231.82 | 143.54 | - | 22.11 | - | - | Upgrade
|
| Debt / Equity Ratio | 1.07 | 1.16 | 1.21 | 0.70 | 0.47 | 0.96 | Upgrade
|
| Debt / EBITDA Ratio | 49.34 | 33.65 | 50.40 | 22.86 | 4.01 | 5.87 | Upgrade
|
| Debt / FCF Ratio | 211.20 | 134.50 | - | 11.37 | - | - | Upgrade
|
| Net Debt / Equity Ratio | 0.29 | 0.28 | 0.31 | -0.23 | 0.00 | 0.41 | Upgrade
|
| Net Debt / EBITDA Ratio | 13.83 | 8.29 | 13.47 | -8.05 | -0.03 | 2.49 | Upgrade
|
| Net Debt / FCF Ratio | 57.60 | 32.61 | -8.17 | -3.79 | 1.92 | -18.96 | Upgrade
|
| Asset Turnover | 0.46 | 0.49 | 0.46 | 0.55 | 0.72 | 0.84 | Upgrade
|
| Inventory Turnover | 8.34 | 7.66 | 6.96 | 7.07 | 6.92 | 6.80 | Upgrade
|
| Quick Ratio | 1.02 | 1.03 | 0.96 | 0.93 | 1.08 | 1.06 | Upgrade
|
| Current Ratio | 1.11 | 1.12 | 1.07 | 1.03 | 1.25 | 1.25 | Upgrade
|
| Return on Equity (ROE) | 0.42% | 0.72% | 0.56% | -22.52% | 3.78% | 6.02% | Upgrade
|
| Return on Assets (ROA) | -0.03% | 0.12% | -0.30% | -0.30% | 1.74% | 2.75% | Upgrade
|
| Return on Invested Capital (ROIC) | -0.09% | 0.41% | -1.43% | -1.54% | 5.47% | 7.32% | Upgrade
|
| Return on Capital Employed (ROCE) | -0.10% | 0.50% | -1.40% | -1.90% | 8.20% | 13.00% | Upgrade
|
| Earnings Yield | -0.00% | 0.46% | 0.41% | -29.70% | 2.23% | 3.34% | Upgrade
|
| FCF Yield | 0.59% | 1.10% | -4.39% | 5.71% | -0.31% | -2.88% | Upgrade
|
| Dividend Yield | 0.25% | 0.37% | 0.40% | - | 0.23% | 0.35% | Upgrade
|
| Payout Ratio | - | 963.58% | 992.70% | - | 241.13% | 132.63% | Upgrade
|
| Buyback Yield / Dilution | 0.64% | -0.01% | -1.93% | -1.30% | -0.40% | 2.99% | Upgrade
|
| Total Shareholder Return | 0.89% | 0.36% | -1.53% | -1.30% | -0.17% | 3.34% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.